Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,593.50
Bid: 1,593.50
Ask: 1,594.00
Change: -15.00 (-0.93%)
Spread: 0.50 (0.031%)
Open: 1,604.50
High: 1,609.00
Low: 1,586.50
Prev. Close: 1,608.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Citigroup And Goldman Downgrade Property Firms

Fri, 25th Jan 2019 09:47

LONDON (Alliance News) - The following London-listed shares received analyst recommendations Friday morning and late Thursday:----------FTSE 100----------GOLDMAN RAISES LAND SECURITIES TO 'NEUTRAL' ('SELL') - TARGET 769 (788) PENCE----------CITIGROUP CUTS LAND SECURITIES TO 'SELL' ('NEUTRAL') - TARGET 743 (974) PENCE----------GOLDMAN CUTS BRITISH LAND PRICE TARGET TO 589 (620) PENCE - 'NEUTRAL'----------CITIGROUP CUTS BRITISH LAND TO 'SELL' ('NEUTRAL') - TARGET 452 (647) PENCE----------GOLDMAN CUTS SEGRO PRICE TARGET TO 701 (716) PENCE - 'BUY'----------SOCGEN CUTS ITV TO 'HOLD' ('BUY') - TARGET 138 (190) PENCE----------SHORE CAPITAL RAISES ASTRAZENECA TO 'BUY' ('HOLD')----------HSBC SEES GLAXOSMITHKLINE AS ONE OF THE BEST GLOBAL STOCK IDEAS----------RBC CUTS BHP GROUP PRICE TARGET TO 1500 (1525) PENCE - 'SECTOR PERFORM'----------HSBC RAISES ANGLO AMERICAN PRICE TARGET TO 2120 (2100) PENCE - 'BUY'----------UBS RAISES FRESNILLO TO 'BUY' ('NEUTRAL') - TARGET 1100 (900) PENCE----------JPMORGAN CUTS KINGFISHER PRICE TARGET TO 200 (220) PENCE - 'UNDERWEIGHT'----------GOLDMAN RAISES AB FOODS PRICE TARGET TO 2600 (2500) PENCE - 'NEUTRAL'----------GOLDMAN RAISES SEVERN TRENT PRICE TARGET TO 1847 (1763) PENCE - 'SELL'----------BERNSTEIN CUTS VODAFONE PRICE TARGET TO 225 (235) PENCE - 'OUTPERFORM'----------JPMORGAN CUTS VODAFONE PRICE TARGET TO 230 (240) PENCE - 'OVERWEIGHT'----------DEUTSCHE BANK CUTS ST JAMES'S PLACE PRICE TARGET TO 1070 (1090) PENCE - 'HOLD'----------CREDIT SUISSE CUTS RBS PRICE TARGET TO 280 (295) PENCE - 'NEUTRAL'----------CREDIT SUISSE CUTS LLOYDS PRICE TARGET TO 84 (90) PENCE - 'OUTPERFORM'----------CREDIT SUISSE CUTS BARCLAYS PRICE TARGET TO 190 (210) PENCE - 'NEUTRAL'----------EXANE BNP RAISES HALMA TO 'OUTPERFORM' ('NEUTRAL') - TARGET 1550 (1350) PENCE----------EXANE BNP CUTS SPIRAX-SARCO TO 'UNDERPERFORM' (N) - TARGET 5700 (6300) PENCE----------FTSE 250----------GOLDMAN CUTS INTU PROPERTIES TO 'SELL' ('NEUTRAL') - TARGET 92 (117) PENCE----------CITIGROUP CUTS INTU PROPERTIES TO 'SELL' ('NEUTRAL') - TARGET 69 (190) PENCE----------CITIGROUP CUTS HAMMERSON TO 'SELL' ('NEUTRAL') - TARGET 278 (465) PENCE----------GOLDMAN CUTS HAMMERSON PRICE TARGET TO 367 (441) PENCE - 'NEUTRAL'----------CITIGROUP CUTS GREAT PORTLAND TO 'SELL' ('NEUTRAL') - TARGET 592 (691) PENCE----------GOLDMAN CUTS GREAT PORTLAND PRICE TARGET TO 633 (662) PENCE - 'NEUTRAL'----------GOLDMAN CUTS DERWENT LONDON PRICE TARGET TO 2960 (2976) PENCE - 'NEUTRAL'----------CITIGROUP CUTS DERWENT LONDON TO 'SELL' ('NEUTRAL') - TARGET 2513 (3186) PENCE----------GOLDMAN CUTS SHAFTESBURY PRICE TARGET TO 748 (806) PENCE - 'SELL'----------CITIGROUP CUTS SHAFTESBURY TO 'NEUTRAL' ('BUY') - TARGET 872 (1229) PENCE----------GOLDMAN CUTS BIG YELLOW GROUP PRICE TARGET TO 972 (993) PENCE - 'NEUTRAL'----------UBS CUTS CAPITAL & COUNTIES PRICE TARGET TO 310 (320) PENCE - 'BUY'----------JPMORGAN CUTS TRAVIS PERKINS PRICE TARGET TO 1330 (1400) PENCE - 'NEUTRAL'----------HSBC INITIATES CRANSWICK WITH 'HOLD' - TARGET 2810 PENCE----------HSBC INITIATES DAIRY CREST GROUP WITH 'BUY' - TARGET 570 PENCE----------HSBC INITIATES GREENCORE WITH 'BUY' - TARGET 270 PENCE----------HSBC INITIATES HILTON FOOD WITH 'HOLD' - TARGET 920 PENCE----------EXANE BNP RAISES PHOENIX GROUP TARGET TO 800 PENCE - 'OUTPERFORM'----------UBS CUTS SOPHOS PRICE TARGET TO 400 (440) PENCE - 'BUY'----------LIBERUM RESUMES RESTAURANT GROUP WITH 'HOLD' - TARGET 180 PENCE----------EXANE BNP CUTS SPECTRIS TO 'NEUTRAL' ('OUTPERFORM') - TARGET 2350 (2550) PENCE----------OTHER MAIN MARKET AND AIM----------CREDIT SUISSE CUTS DAILY MAIL PRICE TARGET TO 685 (770) PENCE - 'NEUTRAL'---------BARCLAYS CUTS DAILY MAIL PRICE TARGET TO 570 (605) PENCE - 'UNDERWEIGHT'----------GOLDMAN CUTS SECURE INCOME REIT PRICE TARGET TO 417 (446) PENCE - 'BUY'----------RBC CUTS FEVERTREE DRINKS PRICE TARGET TO 3400 (3600) PENCE - 'OUTPERFORM'----------DEUTSCHE BANK RAISES FEVERTREE DRINKS TARGET TO 2800 (2700) PENCE - 'HOLD'----------BERENBERG RAISES CONNECT GROUP PRICE TARGET TO 40 (35) PENCE - 'HOLD'----------LIBERUM RESUMES BURFORD CAPITAL WITH 'BUY' - TARGET 2300 PENCE----------

More News
21 Jun 2023 11:00

US CDC advisers weigh use of GSK, Pfizer RSV vaccines in older adults

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday will vote on whether to recommend the use of recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.

Read more
21 Jun 2023 09:19

GSK unveils positive trial results for vaccine against RSV

(Sharecast News) - GSK unveiled unveiled successful third phase clinical trial results for its Arexvy vaccine against respiratory syncytial virus in older adults.

Read more
21 Jun 2023 08:20

TOP NEWS: GSK reports positive data for RSV Arexvy vaccine

(Alliance News) - GSK PLC on Wednesday reported positive data for Arexvy, its respiratory syncytial virus vaccine for older adults.

Read more
20 Jun 2023 17:20

Miners, oil drag London stocks lower after modest China rate cut

Miners down as metal prices fall on strong dollar, China worries

*

Read more
20 Jun 2023 08:33

Lab crunch: British science has nowhere to go

OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.

Read more
16 Jun 2023 17:01

LONDON MARKET CLOSE: FTSE 100 ends a week of rate decisions higher

(Alliance News) - Stocks in London ended largely higher on Friday, following a busy week centred on the interest rate decisions of three major central banks.

Read more
16 Jun 2023 11:59

GSK cancer drug delay by FDA not "necessarily a red flag"

(Alliance News) - GSK PLC must gain approval for its "centrepiece" cancer drug momelotinib to validate its mergers & acquisitions pipeline but the extension of its review period in the US does not automatically spell trouble, according to analysis from Shore Capital on Friday.

Read more
16 Jun 2023 07:47

FDA extends review period of GSK blood cancer drug momelotinib

(Sharecast News) - GSK said on Friday that the US Food and Drug Administration has extended the review period of its new drug application for momelotinib, which is used to treat a blood cancer called myelofibrosis.

Read more
16 Jun 2023 07:42

IN BRIEF: GSK says FDA extending review period for blood cancer drug

GSK PLC - Brentford, England-based pharmaceutical company - Says US Food & Drug Administration has extended the review period of the new drug application for momelotinib by three months. Extension aims to provide time to review recently submitted data. The extended action date is September 16. Momelotinib uses "novel mechanism of action" to treat myelofibrosis, a rare blood cancer, as well as progressive anaemia which characterises the disease. Myelofibrosis affects approximately 25,000 US patients. The drug is not currently approved in any markets. GSK says it is "confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review."

Read more
9 Jun 2023 06:53

AstraZeneca hails RSV drug nirsevimab recommendation by FDA committee

(Alliance News) - AstraZeneca PLC on Thursday said that a US Food & Drug Administration committee unanimously recommended its antibody nirsevimab.

Read more
8 Jun 2023 12:09

London "still attractive" place to list, as IPO activity trickles back

(Alliance News) - A recent revival of initial public offerings in London's equity markets is encouraging evidence that the city still holds appeal on the global stage, analysts contended.

Read more
7 Jun 2023 09:22

EU approves its first vaccine for common respiratory virus RSV

June 7 (Reuters) - European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.

Read more
7 Jun 2023 09:10

LONDON MARKET OPEN: Stocks head lower amid global growth fears

(Alliance News) - Stock prices in London opened in the red on Wednesday, as concerns about interest rate hikes and a global economic slowdown damped risk appetite.

Read more
7 Jun 2023 07:59

TOP NEWS: GSK's Arexvy is first EU-approved RSV jab for older adults

(Alliance News) - GSK PLC on Wednesday announced that its RSV vaccine Arexvy has become the first EU-backed vaccine against the respiratory syncytial virus for adults aged 60 and older.

Read more
7 Jun 2023 07:34

GSK gets European approval for RSV vaccine

(Sharecast News) - Pharmaceuticals giant GSK announced on Wednesday that the European Commission has granted authorisation for 'Arexvy' - an adjuvant respiratory syncytial virus (RSV) vaccine - for active immunisation to prevent RSV-caused lower respiratory tract disease (LRTD) in adults 60 and older.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.